Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin v8 and v1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. The company said interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily dose, representing a 50% objective response rate at the highest dose tested to date. Also, PLN-101095 was generally well tolerated across all doses.
PLN-101095 is an oral small molecule inhibitor of integrins v8 and v1. It is currently being evaluated in an ongoing first-in human Phase 1 dose-escalation trial. The Phase 1 trial is currently enrolling the fourth of five potential cohorts.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com